Trials / Completed
CompletedNCT02580864
Bologna IBD Markers
Predictive Factors of Anti-TNFalfa-induced Deep Remission in Crohn's Disease
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 84 (actual)
- Sponsor
- Société des Produits Nestlé (SPN) · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Individuate possible predictive factors of anti-TNFalfa-induced deep remission in Crohn's disease.
Detailed description
This trial will be exploratory, open in vitro study on human tissues. 120 patients will be enrolled (Caucasian, male/female,18-65 years old) with moderate-severe active Crohns disease and with indication for anti-TNF therapy according to the normal clinical practice. Simultaneously, 30 no-IBD controls with no GI disorders, as defined by medical history and standard clinical chemistry values, afferent to the out-patient clinic will be enrolled.
Conditions
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2018-10-01
- Completion
- 2019-01-01
- First posted
- 2015-10-20
- Last updated
- 2019-07-23
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT02580864. Inclusion in this directory is not an endorsement.